TLSI · TriSalus Life Sciences, Inc. · Webcasts, Transcripts & Audio
$4.15
-0.16 (-3.71%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 6, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our continuation as a going concern is dependent on our ability to generate sufficient cash flows from operations and/or obtain additional capital through equity or debt financings, partnerships, collaborations, strategic alliances and/or licensing arrangements to carry out our long-term business strategy. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than fair value for such assets and less than the value at which such assets are carried on our financial statements, and it is likely that investors will lose all or a part of their investment. There can be no assurances that we will be successful in any of these respects, or that we will be able to continue to obtain outside capital in the future or do so on terms that are acceptable to us.”View the 10-Q filed Aug 6, 2026
Market Cap
$267.23M
Shares
61.57M
Volume · Oct 1
273.18K
Avg daily vol (3M)
288.7K
TriSalus Life Sciences, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for TriSalus Life Sciences, Inc. (TLSI), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲32.4%
$5.19M
−$1.43M
'23 Q3
23-11-14
·
$5.72M
−$35.64M
'23 Q4
24-03-12
▲116.4%
$6.46M
−$13.21M
'24 Q1
24-04-01
▲59.7%
$7.36M
−$4.33M
'24 Q2
24-08-15
▲41.5%
$7.35M
−$2.40M
'24 Q3
24-11-14
▲42%
$9.17M
−$10.38M
'25 Q1
25-05-15
▲52.3%
$11.21M
−$8.29M
'25 Q2
25-08-12
▲57.4%
$11.57M
−$10.81M
'25 Q3
25-11-12
▲59.8%
$13.21M
−$9.75M
'25 Q4
26-03-05
▼2.9%
$8.90M
$1.54M
'26 Q1
26-05-12
LATEST
▲1.7%
$11.41M
−$9.19M
'26 Q2
26-08-06
Conference
Investor event
2026-09-14
TriSalus Life Sciences, Inc. (TLSI) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
TriSalus Life Sciences, Inc. (TLSI) August 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript
Confident tone
CMS G-code expanding reimbursement into OBL setting
Quarterly revenue growth and commercial momentum
PEDD platform and pressure-enabled drug delivery technology
Revenue
$11.41M
▲ 1.7% YoY Diluted EPS
$-0.16
Gross margin
86.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
TriSalus Life Sciences, Inc. (TLSI) Q1 2026 Earnings Call Transcript
Positive tone
Real-world evidence study / PEDD data
New applications / market expansion
Commercial organization expansion
Revenue
$8.90M
▼ 2.9% YoY Diluted EPS
$0.03
Gross margin
86.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-05
TriSalus Life Sciences, Inc. (TLSI) Q4 2025 Earnings Call Transcript
Confident tone
Commercial expansion / sales force
New applications beyond liver
Revenue growth and guidance
Revenue
$13.21M*
▲ 59.8% YoY Gross margin
86.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
TriSalus Life Sciences, Inc. (TLSI) Q3 2025 Earnings Call Transcript
Confident tone
TriNav platform expansion
Genicular artery embolization (GAE) / knee osteoarthritis
Revenue growth and guidance
Revenue
$11.57M
▲ 57.4% YoY Diluted EPS
$-0.96
Gross margin
83.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
TriSalus Life Sciences, Inc. (TLSI) Q2 2025 Earnings Call Transcript
Confident tone
TriNav revenue growth and commercial momentum
Nelitolimod partnership strategy
TriNav FLX and product portfolio expansion
Revenue
$11.21M
▲ 52.3% YoY Diluted EPS
$-0.27
Gross margin
83.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
TriSalus Life Sciences, Inc. (TLSI) Q1 2025 Earnings Call Transcript
Positive tone
Liver embolization / TriNav adoption
Nelitolimod and partnership strategy
Product portfolio expansion
Revenue
$9.17M
▲ 42% YoY Diluted EPS
$-0.39
Gross margin
83.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q3
2024-11-14
TriSalus Life Sciences, Inc. (TLSI) Q3 2024 Earnings Call Transcript
Confident tone
PERIO-03 pancreatic trial (nelitolimod)
PROTECT registry for multinodular goiter (thyroid)
Product launches (TriNav Large, TriGuide, TriNav 2.0)
Revenue
$7.35M
▲ 41.5% YoY Diluted EPS
$-0.12
Gross margin
86.3%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-15
TriSalus Life Sciences, Inc. (TLSI) Q2 2024 Earnings Call Transcript
Confident tone
Nelitolimod pipeline (PERIO trials)
PEDD / TriNav technology differentiation
Thyroid / PROTECT opportunity
Revenue
$7.36M
▲ 59.7% YoY Diluted EPS
$-0.21
Gross margin
87.6%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-01
TriSalus Life Sciences, Inc. (TLSI) Q1 2024 Earnings Call Transcript
Confident tone
Revenue growth and TriNav performance
Reimbursement and clinical data for TriNav
TriNav Large product launch
Revenue
$6.46M
▲ 116.4% YoY Diluted EPS
$-0.60
Gross margin
85.0%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-12
TriSalus Life Sciences, Inc. (TLSI) Q4 2023 Earnings Call Transcript
Confident tone
Revenue Growth and TriNav Sales
Nelitolimod and Pancreatic Program
Clinical Pipeline / PERIO Trials
Revenue
$5.72M*
Gross margin
89.8%
Rev · 4q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-14
TriSalus Life Sciences, Inc. (TLSI) Q3 2023 Earnings Call Transcript
Revenue
$5.19M
▲ 32.4% YoY Diluted EPS
$-0.14
Gross margin
88.7%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–13 of 13 webcasts